Renin inhibition is an active clinical strategy in the control of blood pressure and hypertension that has been achieved through the use of renin inhibitors such as Aliskiren, otherwise referred to as Tekturna® or Rasilez® [231], whose action inhibits the activity ACE-1, thus preventing the conversion of angiotensin I to angiotensin II [232]. This evidence concerns the gene REN and hypertensive disorder.